TOP TEN perturbations for 1553059_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553059_at
Selected probe(set): 1553059_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553059_at (1553059_at) across 6672 perturbations tested by GENEVESTIGATOR:

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):-2.1505804
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

FGFR3 (S249C) overexpression study 1 / control vector transfected TERT-NHUC cell sample

Relative Expression (log2-ratio):-2.1173487
Number of Samples:3 / 3
Experimental FGFR3 (S249C) overexpression study 1
Normal human urothelial cell line TERT-NHUC stably transduced to express Fibroblast Growth Factor Receptor 3 (FGFR3) mutation S249C.
Control control vector transfected TERT-NHUC cell sample
Normal human urothelial cell line TERT-NHUC stably transduced to express an empty vector (pFB).

cutaneous T-cell lymphoma study 1 (tumor phase) / cutaneous T-cell lymphoma study 1 (patch phase)

Relative Expression (log2-ratio):-1.7307615
Number of Samples:4 / 2
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control cutaneous T-cell lymphoma study 1 (patch phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the patch phase.

keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2

Relative Expression (log2-ratio):-1.6871195
Number of Samples:2 / 2
Experimental keratinocyte differentiation study 2 (KLF4 siRNA)
KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency.
Control keratinocyte differentiation study 2
Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency.

cutaneous T-cell lymphoma study 1 (tumor phase) / cutaneous T-cell lymphoma study 1 (plaque phase)

Relative Expression (log2-ratio):-1.5863886
Number of Samples:4 / 7
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-1.4382
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

psoriasis study 5 (NCT00867100; lesional; baseline) / psoriasis study 5 (NCT00867100; non-lesional; baseline)

Relative Expression (log2-ratio):1.429975
Number of Samples:24 / 24
Experimental psoriasis study 5 (NCT00867100; lesional; baseline)
Lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from lesional skin at baseline.
Control psoriasis study 5 (NCT00867100; non-lesional; baseline)
Non-lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from uninvolved, non-lesional skin at baseline.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-1.4288712
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

psoriasis study 11 (lesional; baseline) / psoriasis study 11 (non-lesional; baseline)

Relative Expression (log2-ratio):1.4216738
Number of Samples:25 / 24
Experimental psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.
Control psoriasis study 11 (non-lesional; baseline)
Non-lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)

Relative Expression (log2-ratio):-1.3619318
Number of Samples:10 / 2
Experimental psoriasis study 24 (lesional; etanercept; 12wk; 50mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 50 mg etanercept and assigned as non-responders. Etanercept was administered subcutaneously in dose of 50 mg twice weekly. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 45 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.